30 Day Trial

Medicrea Reports 3Q15 Revenue +12%

Share:

Medicrea posted 3Q15 revenue of €7.1MM (~US $8MM), +12% from 3Q14. 

Year to date revenue of €20.9 (~$23.7MM) represents +18% growth vs. the prior period on an as-reported basis. 

For 3Q15, U.S. sales comprised 63% of total revenue and company leadership reports a continued increase in France market share. In the EU, first implants manufactured using a 3D printer are slated for launch in early 2016.

Source: Medicrea